

Issue Tracker



Together,
there's
something
science
can do.

Issue Tracker 2024/005
July 8th, 2024

[C-Path and Centogene partner to advance drug development for lysosomal diseases:](#) The memorandum of understanding entered into by the Critical Path-Institute (C-Path) and Centogene seeks to bolster genetic and real-world data to solve challenges involved in the development of safe effective treatments for lysosomal diseases (LD). One of many collaborative activities to be pursued will be data enrichment and linkage that will integrate and enrich data within the collaboration's targeted LDs.

[Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria:](#) The collaboration will enable Eli Lilly to leverage OpenAI's generative AI to invent novel antimicrobials for treating pathogens that are drug resistant. Antimicrobial resistance affects countries in all regions and of all income levels but is acute in low- and middle-income countries due to poverty and inequality.

[BenevolentAI and AstraZeneca collaboration success continues as novel target progressed:](#) AstraZeneca has added a novel target for systemic lupus erythematosus to its discovery portfolio through its collaboration with Benevolent AI. This is the second target selected this year from this collaboration. The novel target was discovered with BenevolentAI's AI-drug discovery platform and then validated experimentally by AstraZeneca.

[Collaboration leads to creation of potent therapy candidate for fatal prion diseases:](#) A collaboration between researchers from the Broad Institute and Whitehead Institute developed a set of molecular tools titled CHARMs (Coupled Histone tail for Autoinhibition Release of Methyltransferase). The tool, a potent therapy candidate for fatal prion disease, functions by turning off disease-causing genes like the prion protein gene. Jonathan Weissman of the Whitehead Institute contributed his lab's tool building experience while Eirc Minkel and Sonia Vallabh of the Broad institute contributed their knowledge of the disease.

[DiaGen Ai Inc. Announces Research Collaboration with the Structural Genomics Consortium at UNC Chapel Hill:](#) The collaboration will aim to develop DiaGen's AI generated library of designed peptides in order to validate selective KRAS binders able to induce degradation of cancer-causing mutant *KRAS-G12D. Progress will be shared through joint publications in order to allow the scientific community to benefit from the collaboration's discoveries.